International Journal of Hematology

, Volume 87, Issue 4, pp 446–448

Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia

  • Kazuma Ohyashiki
  • Toru Kiguchi
  • Yoshikazu Ito
  • Hiroaki Fujimoto
  • Akihiko Gotoh
  • Tetsuzo Tauchi
  • Keisuke Miyazawa
  • Yukihiko Kimura
  • Junko H. Ohyashiki
Letter to the Editor

References

  1. 1.
    Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–53.PubMedCrossRefGoogle Scholar
  2. 2.
    James C, Ugo V, Le Couédic J-P, Staerk J, Delhoummeau F, Flacount C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434:1144–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Ohyashiki K, Aota Y, Akahane D, Gotoh A, Ohyashiki JH. JAK2V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia. 2007;21:1097–9.PubMedGoogle Scholar
  4. 4.
    Ohyashiki K, Ito Y, Hori K, Sato K, Makino T, Ohyashiki JH. Thrombosis can occur at any phase of essential thrombocythemia with JAK2V617F mutation: a single institutional study in Japan. Leukemia. 2007;21:1570–1.PubMedCrossRefGoogle Scholar
  5. 5.
    Finazzi G, Rambaldi A, Guerini V, Carobbio A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007;92:135–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood. 2007;105:2310–3.CrossRefGoogle Scholar
  7. 7.
    Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–68.PubMedCrossRefGoogle Scholar
  8. 8.
    Tefferi A, Thiele J, Orazi A, et al. Proposals amd rationale for revison of the World Heal Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Michiels JJ, De Raeve H, Hebeda K, et al. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloprolierative disorders. Leuk Res. 2007;31:1031–8.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2008

Authors and Affiliations

  • Kazuma Ohyashiki
    • 1
  • Toru Kiguchi
    • 1
  • Yoshikazu Ito
    • 1
  • Hiroaki Fujimoto
    • 1
  • Akihiko Gotoh
    • 1
  • Tetsuzo Tauchi
    • 1
  • Keisuke Miyazawa
    • 1
  • Yukihiko Kimura
    • 1
  • Junko H. Ohyashiki
    • 2
  1. 1.Hematology DivisionTokyo Medical UniversityTokyoJapan
  2. 2.Intractable Immune System Diseases Research CenterTokyo Medical UniversityTokyoJapan

Personalised recommendations